Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Relapse · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Microbiological response: eradicated. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Hospital admissions · bronchiectasis
1 finding from 1 review
Death · bronchiectasis
1 finding from 1 review
Quality of life · bronchiectasis
1 finding from 1 review
Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response rate ‐ improvement in sputum purulence · adults with bronchiectasis
It is very uncertain whether polymyxins changes response rate ‐ improvement in sputum purulence compared with aminoglycosides (very low certainty).
1 finding from 1 review
Response rate ‐ P aeruginosa eradication · adults with bronchiectasis
It is very uncertain whether polymyxins changes response rate ‐ P aeruginosa eradication compared with aminoglycosides (very low certainty).
1 finding from 1 review
Deaths · adults with bronchiectasis
1 finding from 1 review
Quality of life · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to lower response rate ‐ treatment failure compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ microbiological response · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to higher response rate ‐ microbiological response compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ improvement in sputum purulence (excellent) · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
It is very uncertain whether fluoroquinolones changes response rate ‐ improvement in sputum purulence (excellent) compared with amoxicillin (very low certainty).
1 finding from 1 review
Deaths · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Quality of life · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with bronchiectasis
1 finding from 1 review
Symptomatic cure with all exclusions treated as failures · patients with Clostridium difficile‐associated diarrhoea in adults
Metronidazole probably leads to lower symptomatic cure with all exclusions treated as failures compared with vancomycin (moderate certainty).
1 finding from 1 review